Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.21.2
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents [note 5] $ 33,312 $ 35,853
Grant receivable [note 2] 151  
Prepaid expenses and other assets 1,270 1,122
Total current assets 34,733 36,975
Property and equipment, net 21 42
Right-of-use assets [note 7] 79 146
Other assets and restricted cash [note 5] 235 237
License agreement [note 3 and 4] 1,697 1,864
Goodwill [note 4] 1,034 1,034
Total assets 37,799 40,298
Current liabilities:    
Accounts payable 815 332
Accrued liabilities other 194 584
Accrued clinical liabilities 757 453
Accrued compensation 1,241 1,474
Current portion of long-term obligations [note 7] 69 92
Total current liabilities 3,076 2,935
Long-term obligations [note 7] 23 77
Total liabilities 3,099 3,012
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 9,453,542 issued and outstanding at September 30, 2021 and 6,111,735 issued and outstanding at December 31, 2020. 79 76
Additional paid-in capital 121,052 97,640
Accumulated deficit (86,435) (60,434)
Accumulated other comprehensive income 4 4
Total stockholders' equity 34,700 37,286
Total liabilities and stockholders' equity 37,799 40,298
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value